Once daily oral relugolix combination therapy versus placebo in patients with endometriosis-associated pain: two replicate phase 3, randomised, double-blind, studies (SPIRIT 1 and 2) (2022)
- Authors:
- Autor USP: ABRÃO, MAURICIO SIMÕES - FM
- Unidade: FM
- DOI: 10.1016/S0140-6736(22)00622-5
- Subjects: CO-TERAPIA; GONADOTROFINAS; ENDOMETRIOSE; PLACEBOS
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Source:
- Este periódico é de assinatura
- Este artigo é de acesso aberto
- URL de acesso aberto
- Cor do Acesso Aberto: hybrid
- Licença: cc-by
-
ABNT
GIUDICE, Linda C et al. Once daily oral relugolix combination therapy versus placebo in patients with endometriosis-associated pain: two replicate phase 3, randomised, double-blind, studies (SPIRIT 1 and 2). Lancet, v. 399, n. 10343, p. 2267-2279, 2022Tradução . . Disponível em: https://doi.org/10.1016/S0140-6736(22)00622-5. Acesso em: 12 jan. 2026. -
APA
Giudice, L. C., As-sanie, S., Ferreira, J. C. A., Becker, C. M., Abrão, M. S., Lessey, B. A., et al. (2022). Once daily oral relugolix combination therapy versus placebo in patients with endometriosis-associated pain: two replicate phase 3, randomised, double-blind, studies (SPIRIT 1 and 2). Lancet, 399( 10343), 2267-2279. doi:10.1016/S0140-6736(22)00622-5 -
NLM
Giudice LC, As-sanie S, Ferreira JCA, Becker CM, Abrão MS, Lessey BA, Brown E, Dynowski K, Wilk K, Li Y. Once daily oral relugolix combination therapy versus placebo in patients with endometriosis-associated pain: two replicate phase 3, randomised, double-blind, studies (SPIRIT 1 and 2) [Internet]. Lancet. 2022 ; 399( 10343): 2267-2279.[citado 2026 jan. 12 ] Available from: https://doi.org/10.1016/S0140-6736(22)00622-5 -
Vancouver
Giudice LC, As-sanie S, Ferreira JCA, Becker CM, Abrão MS, Lessey BA, Brown E, Dynowski K, Wilk K, Li Y. Once daily oral relugolix combination therapy versus placebo in patients with endometriosis-associated pain: two replicate phase 3, randomised, double-blind, studies (SPIRIT 1 and 2) [Internet]. Lancet. 2022 ; 399( 10343): 2267-2279.[citado 2026 jan. 12 ] Available from: https://doi.org/10.1016/S0140-6736(22)00622-5 - Endometriose: Aspectos imunológicos e moleculares
- Addition of MCP-1 and MIP-3β to the IL-8 appraisal in peritoneal fluid enhances the probability of identifying women with endometriosis
- Endometriose intestinal: resultados do tratamento cirúrgico
- Endometriose profunda
- World Endometriosis Society consensus on the classification of endometriosis
- Role of Eutopic Endometrium in Pelvic Endometriosis
- Ten Principles for Safe Surgical Treatment of Ovarian Endometriosis
- Initial Accuracy of and Learning Curve for Transvaginal Ultrasound with Bowel Preparation for Deep Endometriosis in a US Tertiary Care Center
- Long-term safety and efficacy of elagolix treatment in women with endometriosis associated pain: primary results from two phase 3 extension studies
- Fatores ambientais e endometriose: um ponto de vista [Editorial]
Informações sobre o DOI: 10.1016/S0140-6736(22)00622-5 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
